Reacx Pharms

Reacx Pharms is a Seattle-based biotechnology company specializing in the discovery of covalent small molecule therapeutics for challenging disease targets. The company leverages a proprietary chemoproteomics platform, developed from research at the University of Washington, to identify novel reactive sites on proteins involved in oncology and immunology. By utilizing high-throughput screening of covalent libraries, Reacx aims to develop highly selective and potent inhibitors that overcome the limitations of traditional non-covalent drugs. Their approach focuses on undruggable proteins, particularly kinases, to provide new treatment options for patients with high unmet medical needs. The company is backed by leading life science investors and continues to advance its internal pipeline toward clinical development.